October 27, 2025

How Hormones May Influence Tirzepatide Outcomes

Researchers show how reproductive stage and hormone therapy influence weight-loss outcomes in women treated with tirzepatide.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 23, 2025

Same Disease, Different DNA

Study finds Chinese heart disease patients have four times more rare genetic variants than UK counterparts

The Pathologist

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 16, 2025

Comprehensive Review Identifies Key Neonatal Death Risks

Review grades evidence on neonatal mortality across 64 reviews; methods and gaps outlined.

Conexiant

October 16, 2025

New Criteria, New Numbers on Obesity

A Lancet Commission definition integrating BMI with anthropometric measures increased obesity prevalence by ~60% in a major US cohort, identifying previously unrecognized high-risk patients while introducing distinct clinical phenotypes.

Conexiant

October 16, 2025

Cardiac Rehab Participation One-Third Lower in Women

Women remain underrepresented in cardiac rehabilitation across all stages of participation.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant